anti-Fcgamma receptor I (Gilboa Therapeutics/Tel Aviv University)

N/A

Report date: 2025/01/26 18:54:05

Base Information

Drug Nameanti-Fcgamma receptor I (Gilboa Therapeutics/Tel Aviv University)
Drug Alias Nameanti-Fc gamma RI (Gilboa Therapeutics/Tel Aviv University)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionHigh affinity immunoglobulin gamma Fc receptor I antagonists
TargetsHigh affinity immunoglobulin gamma Fc receptor I
Therapy Area/IndicationsSolid tumoursLymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryIsrael
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesTel Aviv University
China Registration ClassN/A

Develop Information

Active CompaniesGilboa Therapeutics LtdTel Aviv University
Inactive CompaniesN/A
Active IndicationsSolid tumoursLymphoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A